Erythrocytosis on Testosterone Cypionate (2026 Data)

How common is erythrocytosis on testosterone cypionate?

Erythrocytosis is the most common side effect of testosterone therapy, according to a 2023 clinical guide [4]. The clearest controlled number is a mean change rather than a patient count, and it is not cypionate-specific: across 29 placebo-controlled randomized trials with 3,393 men, intramuscular testosterone enanthate/cypionate raised mean hematocrit by 4.0% compared with placebo (95% CI 2.9 to 5.1) [1]. Gel raised it by 3.0% and patch by 1.4%; intramuscular enanthate/cypionate rose significantly more than patch, while other pairings were not significantly different [1].

A retrospective single-center review of 178 hypogonadal men followed for 3 years found hematocrit above 50% in 66.7% of men on injectable testosterone, 12.8% on gels, and 35.1% on pellets [2]. That comparison is not randomized, and the injection group was younger (mean 42.5 years versus about 54 years) with higher baseline hematocrit, so the gap between routes cannot be attributed to formulation alone [2].

A 2025 systematic review of drug-induced erythrocytosis reported rates up to 66.7% in men on prescription testosterone, with intramuscular formulations, higher doses, and older age associated with increased risk [7]. A 2018 review found short-acting injectable formulations had the highest incidence [5]. A 2015 review put the risk differently: men on testosterone replacement had a 315% greater risk of erythrocytosis defined as hematocrit above 0.52 than controls, and all formulations raised hemoglobin and hematocrit, with injectables the most [8]. The Endocrine Society guideline recommends against starting testosterone therapy in men with elevated hematocrit [9].

What does the Depo-Testosterone label say?

The Depo-Testosterone label lists polycythemia among adverse reactions and says to check hemoglobin and hematocrit periodically during long-term use [3]. The label also says venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, have been reported with testosterone products, and it says to discontinue treatment if a VTE is suspected [3].

How high is too high, and how is it managed?

A 2023 clinical guide says providers should decrease or discontinue testosterone therapy if hematocrit exceeds 54% until it normalizes [4]. A 2022 review says clinicians will often adjust testosterone dosing, stop therapy, order phlebotomy, or combine these [6]. That review also notes evidence for harm from secondary erythrocytosis during testosterone therapy is scarce and that hematocrit cutoffs in guidelines appear arbitrarily chosen [6]. The Endocrine Society guideline recommends monitoring hematocrit in the first year of therapy [9].

Does erythrocytosis raise clot risk?

The Depo-Testosterone label says VTE has been reported with testosterone products and that increased red blood cell mass may raise thromboembolic risk [3]. Reviews of testosterone-induced erythrocytosis describe the link between elevated hematocrit and VTE as unclear or inconclusive [5][8]. A 2025 systematic review found thromboembolic events in up to 2.7% of men on testosterone therapy [7].